Abstract
Purpose Ezetimibe has been shown to inhibit dietary cholesterol absorption in animal models and humans, but studies on lymphatic lipid transport have not yet been performed. Rats subjected to permanent lymph duct cannulation were used to investigate the effects of ezetimibe on lipid transport. Methods Rats were fed diets with and without ezetimibe (5.0 mg/kg), and their lymph was collected after feeding to quantify lymphatic lipid levels. Total cholesterol content in the intestinal mucosa was also measured. Results Rats that consumed ezetimibe had significantly lower lymphatic total cholesterol transport with the reduction of esterified cholesterol transport. According to the calculation based on cholesterol consumption, ezetimibe reduced the total cholesterol lymphatic recovery rate by 54 %. We also determined that ezetimibe significantly reduced the total cholesterol content in the intestinal mucosa. Conclusion This is the first direct evidence that ezetimibe inhibits esterified but not free cholesterol lymphatic transport in thoracic duct-cannulated rats. The results also indicate that ezetimibe is not involved in the lymphatic transport of triacylglycerols, phospholipids, or a-tocopherol.
| Original language | English |
|---|---|
| Pages (from-to) | 427-431 |
| Number of pages | 5 |
| Journal | Cardiovascular Drugs and Therapy |
| Volume | 26 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Oct 1 2012 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacology
- Cardiology and Cardiovascular Medicine
- Pharmacology (medical)
Cite this
Ezetimibe inhibits lymphatic transport of esterified cholesterol but not free cholesterol in thoracic lymph duct-cannulated rats. / Shirouchi, Bungo; Nakamura, Yuri; Furukawa, Yumiko; Shiraishi, Aya; Tomoyori, Hiroko; Imaizumi, Katsumi; Sato, Masao.
In: Cardiovascular Drugs and Therapy, Vol. 26, No. 5, 01.10.2012, p. 427-431.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Ezetimibe inhibits lymphatic transport of esterified cholesterol but not free cholesterol in thoracic lymph duct-cannulated rats
AU - Shirouchi, Bungo
AU - Nakamura, Yuri
AU - Furukawa, Yumiko
AU - Shiraishi, Aya
AU - Tomoyori, Hiroko
AU - Imaizumi, Katsumi
AU - Sato, Masao
PY - 2012/10/1
Y1 - 2012/10/1
N2 - Purpose Ezetimibe has been shown to inhibit dietary cholesterol absorption in animal models and humans, but studies on lymphatic lipid transport have not yet been performed. Rats subjected to permanent lymph duct cannulation were used to investigate the effects of ezetimibe on lipid transport. Methods Rats were fed diets with and without ezetimibe (5.0 mg/kg), and their lymph was collected after feeding to quantify lymphatic lipid levels. Total cholesterol content in the intestinal mucosa was also measured. Results Rats that consumed ezetimibe had significantly lower lymphatic total cholesterol transport with the reduction of esterified cholesterol transport. According to the calculation based on cholesterol consumption, ezetimibe reduced the total cholesterol lymphatic recovery rate by 54 %. We also determined that ezetimibe significantly reduced the total cholesterol content in the intestinal mucosa. Conclusion This is the first direct evidence that ezetimibe inhibits esterified but not free cholesterol lymphatic transport in thoracic duct-cannulated rats. The results also indicate that ezetimibe is not involved in the lymphatic transport of triacylglycerols, phospholipids, or a-tocopherol.
AB - Purpose Ezetimibe has been shown to inhibit dietary cholesterol absorption in animal models and humans, but studies on lymphatic lipid transport have not yet been performed. Rats subjected to permanent lymph duct cannulation were used to investigate the effects of ezetimibe on lipid transport. Methods Rats were fed diets with and without ezetimibe (5.0 mg/kg), and their lymph was collected after feeding to quantify lymphatic lipid levels. Total cholesterol content in the intestinal mucosa was also measured. Results Rats that consumed ezetimibe had significantly lower lymphatic total cholesterol transport with the reduction of esterified cholesterol transport. According to the calculation based on cholesterol consumption, ezetimibe reduced the total cholesterol lymphatic recovery rate by 54 %. We also determined that ezetimibe significantly reduced the total cholesterol content in the intestinal mucosa. Conclusion This is the first direct evidence that ezetimibe inhibits esterified but not free cholesterol lymphatic transport in thoracic duct-cannulated rats. The results also indicate that ezetimibe is not involved in the lymphatic transport of triacylglycerols, phospholipids, or a-tocopherol.
UR - http://www.scopus.com/inward/record.url?scp=84867983066&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867983066&partnerID=8YFLogxK
U2 - 10.1007/s10557-012-6403-3
DO - 10.1007/s10557-012-6403-3
M3 - Article
C2 - 22798197
AN - SCOPUS:84867983066
VL - 26
SP - 427
EP - 431
JO - Cardiovascular Drugs and Therapy
JF - Cardiovascular Drugs and Therapy
SN - 0920-3206
IS - 5
ER -